This study evaluated the safety of early anti-factor Xa assay–guided enoxaparin dosing for chemoprophylaxis in patients with TBI. We hypothesized that assay-guided chemoprophylaxis would be comparable in the risk of intracranial hemorrhage (ICH) progression to fixed dosing. An observational analysis of adult patients with blunt traumatic brain injury (TBI) was performed at a Level I trauma center from August 2016 to September 2017. Patients in the assay-guided group were treated with an initial enoxaparin dose of 0.5 mg/kg, with peak anti-factor Xa activity measured four hours after the third dose. Prophylactic range was defined as 0.2 to 0.5 IU/mL with a dose adjustment of ± 10 mg based on the assay result. The assay-guided group was compared with historical fixed-dose controls and to a TBI cohort from the most recent Trauma Quality Improvement Project dataset. Of 179 patients included in the study, 85 were in the assay-guided group and 94 were in the fixed-dose group. Compared with the fixed-dose group, the assay-guided group had a lower Glasgow Coma Score and higher Injury Severity Score. The proportion of severe (Abbreviated Injury Score, head ≥3) TBI, ICH progression, and venous thromboembolism rates were similar between all groups. The assay-guided and fixed-dose groups had chemoprophylaxis initiated earlier than the Trauma Quality Improvement Project group. The assay-guided group had the highest percentage of low molecular weight heparin use. Early initiation of enoxaparin anti-factor Xa assay–guided venous thromboembolism chemoprophylaxis has a comparable risk of ICH progression to fixed dosing in patients with TBI. These findings should be validated prospectively in a multicenter study.
Get full access to this article
View all access options for this article.
References
1.
DeMuroJ.P., HannaA.F.Prophylaxis of deep venous thrombosis in trauma patients: a review.J Blood Disord Transfus2013; 4: 2.
2.
GeertsW.H., CodeK.I., JayR.M.A prospective study of venous thromboembolism after major trauma.N Engl J Med1994; 331: 1601–6.
3.
KaufmanH.H., SatterwhiteT., McConnellB.J.Deep vein thrombosis and pulmonary embolism in head injured patients.Angiology1983; 34: 627–38.
4.
DensonK., MorganD., CunninghamR.Incidence of venous thromboembolism in patients with traumatic brain injury.Am J Surg2007; 193: 380–4.
5.
DudleyR.R., AzizI., BonniciA.Early venous thromboembolic event prophylaxis in traumatic brain injury with low-molecular-weight heparin: risks and benefits.J Neurotrauma2010; 27: 2165–72.
6.
GalanL.A.M., Egea-GuerreroJ.J., DiazM.Q.The effectiveness and safety of pharmacological prophylaxis against venous thromboembolism in patients with moderate to severe traumatic brain injury: a systematic review and meta-analysis.J Trauma Acute Care Surg2016; 81: 567–74.
7.
ScuddayT., BraselK., WebbT.Safety and efficacy of prophylactic anticoagulation in patients with traumatic brain injury.J Am Coll Surg2011; 213: 148–53.
8.
PhelanH.A., WolfS.E., NorwoodS.H.A randomized, double-blinded, placebo-controlled pilot trial of anticoagulation in low-risk traumatic brain injury: the delayed versus early enoxaparin prophylaxis i (DEEP I) study.J Trauma Acute Care Surg2012; 73: 1434–41.
JacobsB.N., Cain-NielsenA.H., JakubusJ.L.Unfractionated heparin versus low-molecular-weight heparin for venous thromboembolism prophylaxis in trauma.J Trauma Acute Care Surg2017; 83: 151–8.
12.
ByrneJ.P., GeertsW., MasonS.A.Effectiveness of low-molecular-weight heparin versus unfractionated heparin to prevent pulmonary embolism following major trauma: a propensity-matched analysis.J Trauma Acute Care Surg2017; 82: 252–62.
13.
KwiattM.E., PatelM.S., RossS.E.Is low-molecular-weight heparin safe for venous thromboembolism prophylaxis in patients with traumatic brain injury? A Western Trauma Association multicenter study.J Trauma Acute Care Surg2012; 73: 625–8.
14.
CostantiniT.W., MinE., BoxK.Dose adjusting enoxaparin is necessary to achieve adequate venous thromboembolism prophylaxis in trauma patients.J Trauma Acute Care Surg2013; 74: 128–35.
15.
BickfordA., MajercikS., BledsoeJ.Weight-based enoxaparin dosing for venous thromboembolism prophylaxis in the obese trauma patient.Am J Surg2013; 206: 847–51, discussion 851–2.
16.
SingerG.A., RiggiG., KarcutskieC.A.Anti-Xa-guided enoxaparin thromboprophylaxis reduces rate of deep venous thromboembolism in high-risk trauma patients.J Trauma Acute Care Surg2016; 81: 1101–8.
17.
BerndtsonA.E., CostantiniT.W., LaneJ.If some is good, more is better: an enoxaparin dosing strategy to improve pharmacologic venous thromboembolism prophylaxis.J Trauma Acute Care Surg2016; 81: 1095–100.
18.
LudwigK.P., SimonsH.J., MoneM.Implementation of an enoxaparin protocol for venous thromboembolism prophylaxis in obese surgical intensive care unit patients.Ann Pharmacother2011; 45: 1356–62.
19.
LehrR.Sixteen S-squared over D-squared: a relation for crude sample size estimates.Stat Med1992; 11: 1099–102.
20.
Van BelleG.Statistical Rules of Thumb, 2nd Ed., New Jersey: John Wiley & Sons.2008.
RogersF.B., CipolleM.D., VelmahosG.Practice management guidelines for the prevention of venous thromboembolism in trauma patients: the EAST practice management guidelines work group.J Trauma2002; 53: 142–64.
23.
GeertsW.H., BergqvistD., PineoG.F.Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines.Chest2008; 133: 3815–4535.
24.
NorwoodS.H., McAuleyC.E., BerneJ.D.Prospective evaluation of the safety of enoxaparin prophylaxis for venous thromboembolism in patients with intracranial hemorrhagic injuries.Arch Surg2002; 137: 696–702.
25.
MohseniS., TalvingP., ChanL.Venous thromboembolic events in isolated severe traumatic brain injury.J Emerg Trauma Shock2012; 5: 11.
26.
RonningP., HelsethE., SkagaN-OThe effect of ICP monitoring in severe traumatic brain injury: a propensity scoreweighted and adjusted regression approach.J Neurosurg2018; 131: 1–9.
